FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013005158> ?p ?o ?g. }

• W2013005158 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLMalignant gliomas are one of the most devastating and incurable tumors with approximately 77% of patients dying within first year of diagnosis. This poor prognosis is due to characteristics of glioma cells to proliferate uncontrollably, sustain excessive angiogenesis and invade aggressively. There has been no improvement in survival of glioma patients in past few decades and existing therapies, with tremendous side-effects, have largely failed. This suggests that immediate additional and alternative strategies are warranted to control this deadly malignancy. In this regard, preventing or inhibiting growth and progression of gliomas through non-toxic natural agents is one such strategy. An agent suited ideally against advance glioma is Asiatic Acid (AsA), the active constituent in Centella asiatica; both Centella asiatica extract and pure AsA are extensively used in traditional medicine to treat neurological disorders. Here we analyzed the anti-cancer efficacy of AsA against glioma cells both in vitro and in vivo. AsA treatment (10-100 microM, 6-24 hrs) significantly decreased cell viability in U87, LN18 and U118 glioma cells, together with strong apoptotic cell death. AsA treatment (6 hrs) in glioma cells caused PARP, Bid and caspases (3, 9 and 8) cleavage, activated JNK1/2, and decreased phosphorylated-Akt and survivin. Use of pan-caspase inhibitor (z-VAD.fmk) confirmed that AsA-induced apoptosis is caspase-dependent. Next, we studied whether AsA could target the pro-angiogenic effects of glioma cells. We observed that AsA treatment at non-cytotoxic doses significantly impairs potency of glioma cells (U87 and LN18) to promote capillary formation by HUVEC (human umbilical vein endothelial cells) and HBMEC (human brain microvascular endothelial cells) on matrigel. Further, AsA (5-20 microM) significantly inhibited VEGF-induced growth of HUVEC and HMBEC. We also observed remarkable anti-migratory effects of AsA treatment (5-20 microM) in wound healing assay and anti-invasive potential in Boyden chambers against glioma cells. In a novel assay developed by us, we further established the inhibitory effects of AsA on fibronectin-induced motility in glioma cells. Additional mechanistic studies revealed that AsA strongly increases intracellular Ca++ levels; and antiproliferative and antimigratory effects of AsA were largely compromised in the presence of Ca++ chelating agent BAPTA. We also established for the first time in vivo anti-cancer efficacy of AsA using xenograft model. AsA feeding (30 mg/kg body weight dose in saline) for 5 weeks significantly decreased U87 xenografts volume by 54% (p value less than 0.05) and strongly inhibited tumor vasculature without causing any adverse effects to animals. Together, these results suggest that AsA could be an effective alternative agent against malignant glioma and recommend its clinical use.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3690. doi:10.1158/1538-7445.AM2011-3690" @default.
• W2013005158 created "2016-06-24" @default.
• W2013005158 creator A5027734680 @default.
• W2013005158 creator A5048444823 @default.
• W2013005158 creator A5059572873 @default.
• W2013005158 creator A5089272096 @default.
• W2013005158 date "2011-04-15" @default.
• W2013005158 modified "2023-09-26" @default.
• W2013005158 title "Abstract 3690: Asiatic acid is an effective alternative agent targeting growth, angiogenesis and invasiveness of malignant gliomas" @default.
• W2013005158 doi "https://doi.org/10.1158/1538-7445.am2011-3690" @default.
• W2013005158 hasPublicationYear "2011" @default.
• W2013005158 type Work @default.
• W2013005158 sameAs 2013005158 @default.
• W2013005158 citedByCount "0" @default.
• W2013005158 crossrefType "proceedings-article" @default.
• W2013005158 hasAuthorship W2013005158A5027734680 @default.
• W2013005158 hasAuthorship W2013005158A5048444823 @default.
• W2013005158 hasAuthorship W2013005158A5059572873 @default.
• W2013005158 hasAuthorship W2013005158A5089272096 @default.
• W2013005158 hasConcept C121608353 @default.
• W2013005158 hasConcept C126322002 @default.
• W2013005158 hasConcept C150903083 @default.
• W2013005158 hasConcept C190283241 @default.
• W2013005158 hasConcept C207001950 @default.
• W2013005158 hasConcept C2775975398 @default.
• W2013005158 hasConcept C2778227246 @default.
• W2013005158 hasConcept C2779077069 @default.
• W2013005158 hasConcept C2780394083 @default.
• W2013005158 hasConcept C31573885 @default.
• W2013005158 hasConcept C502942594 @default.
• W2013005158 hasConcept C55493867 @default.
• W2013005158 hasConcept C556039675 @default.
• W2013005158 hasConcept C71924100 @default.
• W2013005158 hasConcept C86803240 @default.
• W2013005158 hasConcept C96232424 @default.
• W2013005158 hasConcept C98274493 @default.
• W2013005158 hasConcept C98424977 @default.
• W2013005158 hasConceptScore W2013005158C121608353 @default.
• W2013005158 hasConceptScore W2013005158C126322002 @default.
• W2013005158 hasConceptScore W2013005158C150903083 @default.
• W2013005158 hasConceptScore W2013005158C190283241 @default.
• W2013005158 hasConceptScore W2013005158C207001950 @default.
• W2013005158 hasConceptScore W2013005158C2775975398 @default.
• W2013005158 hasConceptScore W2013005158C2778227246 @default.
• W2013005158 hasConceptScore W2013005158C2779077069 @default.
• W2013005158 hasConceptScore W2013005158C2780394083 @default.
• W2013005158 hasConceptScore W2013005158C31573885 @default.
• W2013005158 hasConceptScore W2013005158C502942594 @default.
• W2013005158 hasConceptScore W2013005158C55493867 @default.
• W2013005158 hasConceptScore W2013005158C556039675 @default.
• W2013005158 hasConceptScore W2013005158C71924100 @default.
• W2013005158 hasConceptScore W2013005158C86803240 @default.
• W2013005158 hasConceptScore W2013005158C96232424 @default.
• W2013005158 hasConceptScore W2013005158C98274493 @default.
• W2013005158 hasConceptScore W2013005158C98424977 @default.
• W2013005158 hasLocation W20130051581 @default.
• W2013005158 hasOpenAccess W2013005158 @default.
• W2013005158 hasPrimaryLocation W20130051581 @default.
• W2013005158 hasRelatedWork W1509654317 @default.
• W2013005158 hasRelatedWork W1532588118 @default.
• W2013005158 hasRelatedWork W1781516580 @default.
• W2013005158 hasRelatedWork W1986679409 @default.
• W2013005158 hasRelatedWork W2035328939 @default.
• W2013005158 hasRelatedWork W2047752928 @default.
• W2013005158 hasRelatedWork W2084411547 @default.
• W2013005158 hasRelatedWork W2140502982 @default.
• W2013005158 hasRelatedWork W2262236481 @default.
• W2013005158 hasRelatedWork W2285709798 @default.
• W2013005158 hasRelatedWork W2335248711 @default.
• W2013005158 hasRelatedWork W2337739812 @default.
• W2013005158 hasRelatedWork W2586567372 @default.
• W2013005158 hasRelatedWork W2588983857 @default.
• W2013005158 hasRelatedWork W2779679501 @default.
• W2013005158 hasRelatedWork W2905228592 @default.
• W2013005158 hasRelatedWork W2908079756 @default.
• W2013005158 hasRelatedWork W2924217320 @default.
• W2013005158 hasRelatedWork W2953841434 @default.
• W2013005158 hasRelatedWork W3212908194 @default.
• W2013005158 isParatext "false" @default.
• W2013005158 isRetracted "false" @default.
• W2013005158 magId "2013005158" @default.
• W2013005158 workType "article" @default.